Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tango Therapeutics, Inc.
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
October 23, 2026
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
October 16, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 1, 2026
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026
Tango Therapeutics Announces Executive Chair Transition
August 6, 2026
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026